>
Switch to:

Allergy Therapeutics Current Ratio

: 3.17 (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Allergy Therapeutics's current ratio for the quarter that ended in Jun. 2021 was 3.17.

Allergy Therapeutics has a current ratio of 3.17. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Allergy Therapeutics's Current Ratio or its related term are showing as below:

OTCPK:AGYTF' s Current Ratio Range Over the Past 10 Years
Min: 0.43   Med: 2.01   Max: 6.29
Current: 3.17

0.43
6.29

During the past 13 years, Allergy Therapeutics's highest Current Ratio was 6.29. The lowest was 0.43. And the median was 2.01.

OTCPK:AGYTF's Current Ratio is ranked lower than
56% of the 176 Companies
in the Drug Manufacturers industry.

( Industry Median: 2.72 vs. OTCPK:AGYTF: 3.17 )

Allergy Therapeutics Current Ratio Historical Data

The historical data trend for Allergy Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Current Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.67 2.11 2.77 3.03 3.17

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.77 3.83 3.03 4.23 3.17

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Current Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Current Ratio falls into.



Allergy Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Allergy Therapeutics's Current Ratio for the fiscal year that ended in Jun. 2021

Current Ratio (A: Jun. 2021 )=Total Current Assets (A: Jun. 2021 )/Total Current Liabilities (A: Jun. 2021 )
=81.147265077139/25.568022440393
=3.17

Allergy Therapeutics's Current Ratio for the quarter that ended in Jun. 2021 is calculated as

Current Ratio (Q: Jun. 2021 )=Total Current Assets (Q: Jun. 2021 )/Total Current Liabilities (Q: Jun. 2021 )
=81.147265077139/25.568022440393
=3.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Allergy Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)